# *Bcl10* Cas9-KO Strategy

**Designer: Daohua Xu**

**Reviewer: Huimin Su**

**Design Date: 2019-8-14**

# Project Overview

| | |
|---|---|
| **Project Name** | ***Bcl10*** |
| **Project type** | **Cas9-KO** |
| **Strain background** | **C57BL/6JGpt** |

# Knockout strategy

This model will use CRISPR/Cas9 technology to edit the *Bcl10* gene. The schematic diagram is as follows:



# Technical routes

➢ The *Bcl10* gene has 3 transcripts. According to the structure of *Bcl10* gene, exon2 of *Bcl10-201*(ENSMUST00000029842.9) transcript is recommended as the knockout region.The region contains 289bp coding sequence. Knock out the region will result in disruption of protein function.

➢ In this project we use CRISPR/Cas9 technology to modify *Bcl10* gene. The brief process is as follows: CRISPR/Cas9 system were microinjected into the fertilized eggs of C57BL/6JGpt mice. Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6JGpt mice.

# Notice

➢ According to the existing MGI data,about one-third of homozygous null embryos die exhibiting exencephaly. Surviving mutants display immunological defects including severe immunodeficiency, abnormal B cell development and function, and impaired humoral response to bacterial infection.

➢ The *Bcl10* gene is located on the Chr3. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.

➢ This strategy is designed based on genetic information in existing databases.Due to the complexity of biological processes,all risk of the gene knockout on gene transcription, RNA splicing and protein translation cannot be predicted at the existing technology level.

# Gene information （NCBI）

集萃药康 GemPharmatech

## Bcl10 B cell leukemia/lymphoma 10 [Mus musculus (house mouse)]

Gene ID: 12042, updated on 13-Mar-2020

**Summary**

| | |
|---|---|
| **Official Symbol** | Bcl10 provided by MGI |
| **Official Full Name** | B cell leukemia/lymphoma 10 provided by MGI |
| **Primary source** | MGI:MGI:1337994 |
| **See related** | Ensembl:ENSMUSG00000028191 |
| **Gene type** | protein coding |
| **RefSeq status** | VALIDATED |
| **Organism** | Mus musculus |
| **Lineage** | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus |
| **Also known as** | AI132454, BCL-10, C81403, CARMEN, CIPER, CLAP, ME10, cE10 |
| **Expression** | Ubiquitous expression in large intestine adult (RPKM 10.2), bladder adult (RPKM 8.8) and 28 other tissues See more |
| **Orthologs** | human all |

# Transcript information（Ensembl）

The gene has 3 transcripts,all transcripts are shown below:

| Name | Transcript ID | bp | Protein | Biotype | CCDS | UniProt | Flags |
|---|---|---|---|---|---|---|---|
| Bcl10-201 | ENSMUST00000029842.8 | 1949 | 233aa | Protein coding | CCDS17897 | B7ZWE5 Q9Z0H7 | TSL:1 GENCODE basic APPRIS P1 |
| Bcl10-203 | ENSMUST00000198122.1 | 660 | No protein | Processed transcript | - | - | TSL:3 |
| Bcl10-202 | ENSMUST00000197842.1 | 2368 | No protein | Retained intron | - | - | TSL:NA |

The strategy is based on the design of *Bcl10-201* transcript,the transcription is shown below:



# Genomic location distribution



# Protein domain



# Mouse phenotype description(MGI )




*Phenotypes affected by the gene are marked in blue.Data quoted from MGI database(http://www.informatics.jax.org/).*

According to the existing MGI data,about one-third of homozygous null embryos die exhibiting exencephaly. Surviving mutants display immunological defects including severe immunodeficiency, abnormal B cell development and function, and impaired humoral response to bacterial infection.

集萃药康
GemPharmatech

If you have any questions, you are welcome to inquire.
Tel: 400-9660890

集萃药康生物科技
GemPharmatech Co.,Ltd